Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Mar 7;133(10):1003-1004.
doi: 10.1182/blood-2019-01-892695.

Targeting CD20 takes the backseat in CLL

John C Byrd  1
Affiliations
Comment

Targeting CD20 takes the backseat in CLL

John C Byrd. Blood. .

Abstract

In this issue of Blood, Burger and colleagues report results from a randomized phase 2 study combining rituximab and ibrutinib vs ibrutinib alone in high-risk, untreated, and previously treated chronic lymphocytic leukemia (CLL) patients. This well-performed study provides clear guidance to the field of CLL that, unlike chemotherapy, rituximab addition to ibrutinib does not improve progression-free survival (PFS) or overall survival (OS) as compared with ibrutinib alone.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.C.B. has received research funding from Acerta Pharma, Genentech, Janssen, Verestem, and Pharmacyclics. He is or has been a consultant (<5000 dollars) for Acerta Pharma, Pharmacyclics, Jazz pharmaceuticals, Gilead Pharmaceuticals, and Verastem Pharmaceutics for advice on drug development.

Comment on

References

    1. Burger JA, Sivina M, Jain N, et al. . Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011-1019. - PMC - PubMed
    1. Hallek M, Fischer K, Fingerle-Rowson G, et al. ; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174. - PubMed
    1. Goede V, Fischer K, Busch R, et al. . Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110. - PubMed
    1. Byrd JC, Furman RR, Coutre SE, et al. . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. - PMC - PubMed
    1. O’Brien S, Furman RR, Coutre S, et al. . Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910-1919. - PMC - PubMed